Cargando…
Nanoparticles in Antiviral Therapy
In addition to general unavailability of specific antiviral therapeutics for a variety of viral diseases, usage of most antiviral drugs is linked to their limited solubility in aqueous media, short half-life time, and inadequate penetration to specified anatomic compartments. Accordingly, there is c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173505/ http://dx.doi.org/10.1016/B978-0-323-52733-0.00014-8 |
_version_ | 1783524467400507392 |
---|---|
author | Milovanovic, Marija Arsenijevic, Aleksandar Milovanovic, Jelena Kanjevac, Tatjana Arsenijevic, Nebojsa |
author_facet | Milovanovic, Marija Arsenijevic, Aleksandar Milovanovic, Jelena Kanjevac, Tatjana Arsenijevic, Nebojsa |
author_sort | Milovanovic, Marija |
collection | PubMed |
description | In addition to general unavailability of specific antiviral therapeutics for a variety of viral diseases, usage of most antiviral drugs is linked to their limited solubility in aqueous media, short half-life time, and inadequate penetration to specified anatomic compartments. Accordingly, there is continuous effort to improve physicochemical characteristics of existing antiviral drugs. Since nanomaterials display remarkable physical and chemical properties, high surface area to volume ratio, and increased reactivity, new approaches for antiviral therapies include combinations of nanomaterials and current antiviral agents. Multivalent nanostructures, polymers, dendrimers, and liposomes can establish multivalent binding interactions with many biological systems and thus can target pathogenic interactions. There are reports about anitiviral activities of different metal nanoparticles, especially silver nanoparticles and their potential for treatment, prophylaxis, and control of viral infections. Integration of classic antiviral drugs, in the form of multiple ligands, onto nanostructures provides the advantages by creating a high local concentration of active molecules. This article will summarize the antiviral activity of different nanoparticle-based approaches currently available for the treatment of viral infections, and it will discuss metal nanoparticles as possible future antiviral drugs. |
format | Online Article Text |
id | pubmed-7173505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71735052020-04-22 Nanoparticles in Antiviral Therapy Milovanovic, Marija Arsenijevic, Aleksandar Milovanovic, Jelena Kanjevac, Tatjana Arsenijevic, Nebojsa Antimicrobial Nanoarchitectonics Article In addition to general unavailability of specific antiviral therapeutics for a variety of viral diseases, usage of most antiviral drugs is linked to their limited solubility in aqueous media, short half-life time, and inadequate penetration to specified anatomic compartments. Accordingly, there is continuous effort to improve physicochemical characteristics of existing antiviral drugs. Since nanomaterials display remarkable physical and chemical properties, high surface area to volume ratio, and increased reactivity, new approaches for antiviral therapies include combinations of nanomaterials and current antiviral agents. Multivalent nanostructures, polymers, dendrimers, and liposomes can establish multivalent binding interactions with many biological systems and thus can target pathogenic interactions. There are reports about anitiviral activities of different metal nanoparticles, especially silver nanoparticles and their potential for treatment, prophylaxis, and control of viral infections. Integration of classic antiviral drugs, in the form of multiple ligands, onto nanostructures provides the advantages by creating a high local concentration of active molecules. This article will summarize the antiviral activity of different nanoparticle-based approaches currently available for the treatment of viral infections, and it will discuss metal nanoparticles as possible future antiviral drugs. 2017 2017-06-30 /pmc/articles/PMC7173505/ http://dx.doi.org/10.1016/B978-0-323-52733-0.00014-8 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Milovanovic, Marija Arsenijevic, Aleksandar Milovanovic, Jelena Kanjevac, Tatjana Arsenijevic, Nebojsa Nanoparticles in Antiviral Therapy |
title | Nanoparticles in Antiviral Therapy |
title_full | Nanoparticles in Antiviral Therapy |
title_fullStr | Nanoparticles in Antiviral Therapy |
title_full_unstemmed | Nanoparticles in Antiviral Therapy |
title_short | Nanoparticles in Antiviral Therapy |
title_sort | nanoparticles in antiviral therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173505/ http://dx.doi.org/10.1016/B978-0-323-52733-0.00014-8 |
work_keys_str_mv | AT milovanovicmarija nanoparticlesinantiviraltherapy AT arsenijevicaleksandar nanoparticlesinantiviraltherapy AT milovanovicjelena nanoparticlesinantiviraltherapy AT kanjevactatjana nanoparticlesinantiviraltherapy AT arsenijevicnebojsa nanoparticlesinantiviraltherapy |